High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy

Arthritis Research and Therapy

Volumn 11, Issue 2, 2009, Pages

  Hunzelmann, Nicolas ^a   Moinzadeh, Pia ^a   Genth, Ekkehard ^b   Krieg, Thomas ^a   Lehmacher, Walter ^a   Melchers, Inga ^c   Meurer, Michael ^d   Müller Ladner, Ulf ^e   Olski, Thorsten M ^a   Pfeiffer, Christiane ^d   Riemekasten, Gabriela ^f   Schulze Lohoff, Eckhard ^g   Sunderkoetter, Cord ^h   Weber, Manfred ^g   Buslau, Michael ⁱ   Kötter, Ina ^j   Fierlbeck, Gerhard ^j   Reichenberger, Frank ^k   Müller, Adelheid Maria ^l   Meyringer, Rotraud ^l   Worm, Margitta ^f   Klaus, Pascal ^f   Steinbrink, Kerstin ^m   Kuhn, Annegret ^h   Haust, Merle ⁿ   Hein, Rüdiger ^o   Gräfenstein, Kurt ^p   Juche, Aaron ^p   Lorenz, Hans Martin ^q   Blank, Norbert ^q   Hinrichs, Ralf ^r   Walker, Konrad ^s   Scharffetter Kochanek, Karin ^s   Aberer, Elisabeth ^t   Bali, Gabor ^t   Schmidt, Enno ^u   Fiehn, Christoph ^v   Gross, Ludwig ^w   Lehmann, Percy ^x   Stadler, Rudolf ^y   Bartels, Verena ^y   Szeimies, Rolf Markus ^l   Karrer, Sigrid ^l   Seitz, Cornelia ^z   Reich, Kristian ^aa   Foeldvári, Ivan ^ab   Rubbert, Andrea ^a   Böhm, Markus ^h   Saar, Petra ^e   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e KERCKHOFF HEART CENTER   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g KRANKENHAUS MERHEIM   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ Reha Rheinfelden   (Switzerland)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^k JUSTUS LIEBIG UNIVERSITY   (Germany)

^l UNIVERSITY OF REGENSBURG   (Germany)

^m JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁿ HEINRICH HEINE UNIVERSITY   (Germany)

^o LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^p Center of Rheumatology of Brandenburg   (Germany)

^q UNIVERSITY OF HEIDELBERG   (Germany)

^r University of Heidelberg ^*  (Germany)

^s UNIVERSITY OF ULM   (Germany)

^t UNIVERSITY OF GRAZ   (Austria)

^u UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^v Department of Internal Medicine   (Germany)

^w Rheumatology Clinic   (Germany)

^x UNIVERSITY OF WITTEN HERDECKE   (Germany)

^y Clinic of Minden   (Germany)

^z UNIVERSITY OF GÖTTINGEN   (Germany)

^aa DERMATOLOGIKUM HAMBURG   (Germany)

^ab Klinikum Eilbek   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PREDNISONE;

ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; REGISTER; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; REGISTRIES; SCLERODERMA, SYSTEMIC;

EID: 62849100599     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2634     Document Type: Article

References (24)

1. Denton CP Black CM Scleroderma - clinical and pathological advances Best Pract Res Clin Rheumatol 2004, 18:271-290 15158741
2. White B Bauer EA Goldsmith LA Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic sclerosis Arthritis Rheum 1995, 38:351-360 10.1002/art.1780380309 7880189
3. White B Moore WC Wigley FM Xiao HQ Wise RA Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Ann Intern Med 2000, 132:947-954 10858177
4. Steen VD Medsger TA Jr Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis Arthritis Rheum 1998, 41:1613-1619 10.1002/ 1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O 9751093
5. Tashkin DP Elashoff R Clements PJ Goldin J Roth MD Furst DE Arriola E Silver R Strange C Bolster M Seibold JR Riley DJ Hsu VM Varga J Schraufnagel DE Theodore A Simms R Wise R Wigley F White B Steen V Read C Mayes M Parsley E Mubarak K Connolly MK Golden J Olman M Fessler B Rothfield N et al Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 2006, 354:2655-2666 10.1056/NEJMoa055120 16790698
6. Hoogen van den FH Boerbooms AM Swaak AJ Rasker JJ van Lier HJ Putte van de LB Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial Br J Rheumatol 1996, 35:364-372 10.1093/ rheumatology/35.4.364 8624641
7. Hunzelmann N Genth E Krieg T Lehmacher W Melchers I Meurer M Moinzadeh P Müller-Ladner U Pfeiffer C Riemekasten G Schulze-Lohoff E Sunderkoetter C Weber M Worm M Klaus P Rubbert A Steinbrink K Grundt B Hein R Scharffetter-Kochanek K Hinrichs R Walker K Szeimies RM Karrer S Müller A Seitz C Schmidt E Lehmann P Foeldvári I Reichenberger F et al The registry of the German network for systemic scleroderma: Frequency of disease subsets and patterns of organ involvement Rheumatology (Oxford) 2008, 47:1185-1192 2468885 18515867 10.1093/rheumatology/ken179
8. LeRoy EC Black C Fleischmajer R Jablonska S Krieg T Medsger TA Jr Rowell N Wollheim F Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis J Rheumatol 1988, 15:202-205 3361530
9. Bennett RM Scleroderma overlap syndrome Rheum Dis Clin North Am 1990, 16:185-198 2406807
10. Pope JE Scleroderma overlap syndromes Curr Opin Rheumatol 2002, 14:704-710 10.1097/00002281-200211000-00013 12410095
11. Poormoghim H Lucas M Fertig N Medsger TA Jr Systemic sclerosis sine scleroderma: Demographic, clinical, and serologic features and survival in forty-eight patients Arthritis Rheum 2000, 43:444-451 10.1002/ 1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G 10693887
12. Rodnan GP Fennel RH Progressive systemic sclerosis sine scleroderma JAMA 1962, 180:665-670 14493142
13. Giordano M Valentini G Migliaresi S Picillo U Vatti M Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis J Rheumatol 1986, 13:911-916 3546686
14. Alarcon GS Unclassified or undifferentiated connective tissue disease Baillieres Best Pract Res Clin Rheumatol 2000, 14:125-137 10.1053/ berh.1999.0081 10882218
15. LeRoy EC Maricq HR Kahaleh MB Undifferentiated connective tissue syndromes Arthritis Rheum 1980, 23:341-343 10.1002/art.1780230312 7362686
16. Delany AM Brinckerhoff CE Posttranscriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethason in cultured human fibroblasts J Cell Biochem 1992, 50:400-410 10.1002/jcb.240500409 1469071
17. Steen VD Medsger TA Jr Long-term outcomes of scleroderma renal crisis Ann Intern Med 2000, 133:600-603 11033587
18. Pope JE Bellamy N Seibold JR Baron M Ellman M Carette S Smith CD Chalmers IM Hong P O'Hanlon D Kaminska E Markland J Sibley J Catoggio L Furst DE A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma Arthritis Rheum 2001, 44:1351-1358 10.1002/ 1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I 11407694
19. Nadashkevich O Davis P Fritzler M Kovalenko W A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis Clin Rheumatol 2006, 25:205-212 10.1007/ s10067-005-1157-y 16228107
20. Silver RM Warrick JH Kinsella MB Staudt LS Baumann MH Strange C Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease J Rheumatol 1993, 20:838-844 8336309
21. Nihtyanova SI Brough GM Black CM Denton CP Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: A retrospective analysis Rheumatology 2007, 46:442-445 10.1093/rheumatology/kel244 16899504
22. Clements PJ Furst DE Wong WK Mayes M White B Wigley F Weisman MH Barr W Moreland LW Medsger TA Jr Steen V Martin RW Collier D Weinstein A Lally E Varga J Weiner S Andrews B Abeles M Seibold JR High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial Arthritis Rheum 1999, 42:1194-1203 10.1002/ 1529-0131(199906)42:6<1194::AID-ANR16>3.0.CO;2-7 10366112
23. Olski T Hunzelmann N Immunosuppressive and antifibrotic therapy of systemic sclerosis Expert Rev Dermatol 2007, 2:203-215 10.1586/ 17469872.2.2.203
24. Pope JE Ouimet JM Krizova A Scleroderma treatment differs between experts and general rheumatologists Arthritis Rheum 2006, 55:138-145 10.1002/art.21714 16463426